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Impaired fibrinolytic system in ApoE gene-deleted
mice with hyperlipidemia augments deep vein
thrombosis
Jose A. Diaz, MD,a Nicole E. Ballard-Lipka, BS,a Diana M. Farris, LVT,a Angela E. Hawley, MS,a
Shirley K. Wrobleski, BS,a Daniel D. Myers, DVM,a,b Peter K. Henke, MD,a Daniel A. Lawrence, PhD,c
and Thomas W. Wakefield, MD,a Ann Arbor, Mich
Background: Hyperlipidemia increases the level of blood plasminogen activator inhibitor-1 (PAI-1) that is responsible for
regulating fibrinolysis by inhibiting both urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator
(t-PA).While this fibrinolytic pathway iswell known, the roleofPAI-1 in venous thrombosis (VT)underhyperlipidemic conditions
has not been fully established. We sought to determine the effects of PAI-1 in an in vivo hyperlipidemic model of VT.
Methods: C57BL/6 wild-type (WT) mice, apolipoprotein E gene-deleted mice (ApoE-/-) having hyperlipidemia, and PAI-1
gene-deleted (PAI-1-/-) mice were used in this study. Inferior vena cava (IVC) ligation below the level of the renal veins was
performed to create a stasis VT. Endpoints included measuring acute thrombosis (day 2) and chronic thrombosis (days 6 and
14). At euthanasia, blood samples were collected for plasmin and PAI-1 activity. In addition, the IVC and its thrombus were
evaluated for thrombus weight (TW), u-PA activity, and differential leukocyte count while the vein wall only was analyzed for
monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinase (MMP) 2, and MMP-9.
Results:Compared toWT at day 2, ApoE-/-mice demonstrated a statistically significant 14% increase in TW (P< .05) and
a significant 41% increase in circulating PAI-1 activity (P < .05), while showing a trend of decreased plasmin activity. In
addition, TW in ApoE-/-mice was 45% higher than PAI-1-/-mice at day 2 (P < .05), 33% at day 6 (P < .01), and 41%
at day 14 (P < .01). ApoE-/-mice exhibited undetectable levels of u-PA in both vein wall and thrombus, compared to
WT, at all time points. Also, vein wall MMP-2 was significantly decreased by 64% at day 6 (P < .01) and 58% at day 14
(P < .05). MMP-9 was significantly decreased by 71% at day 2 (P < .01) and 48% at day 6 (P < .01), in ApoE-/-mice
compared to WT mice. In addition, in ApoE-/-mice, MCP-1 was significantly decreased by 38% at day 2 (P < .01) and
67% at day 6 (P< .01) vs WTmice. As expected in ApoEmice, following a decrease inMCP-1, monocyte recruitment was
significantly decreased at days 6 (P < .01) and 14 (P < .05).
Conclusions: A significant increase of circulating PAI-1 levels in hyperlipidemicmice correlatedwith an early increase in TWdue to
impaired fibrinolysis. The undetectable levels of u-PA in ApoE-/-mice correlated to a decrease in vein wall MMP-2, MMP-9,
MCP-1, and a decrease in monocyte recruitment diminishing thrombus resolution. (J Vasc Surg 2012;55:815-22.)
Clinical Relevance:Recent studies have presented evidence of a connection between hyperlipidemia and deep vein thrombosis
(DVT). Here we present our findings on characterizing a mouse model of DVT in hyperlipidemia. We found a dysfunction in
the fibrinolytic system in hyperlipidemic mice undergoing venous thrombosis. This information may contribute to a better
understanding of the mechanisms linking hyperlipidemia andDVT. In addition, we believe that our findings represent a solid
characterization of a mouse model for future therapeutic studies involving DVT and hyperlipidemia.
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the formation of or lyse existing thrombus through plas-
min, the enzyme responsible for breaking down fibrin that
forms in layers within a thrombus. This role is maintained
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doi:10.1016/j.jvs.2011.08.038hrough a constant dynamic balance between activators and
nhibitors of fibrinolysis. The leading activators are tissue-
ype plasminogen activator (t-PA) and urokinase-type plas-
inogen activator (u-PA), and one of the key inhibitors is
lasminogen activator inhibitor-1 (PAI-1). PAI-1 is pro-
uced mainly by the endothelium but is also secreted in an
ctive form by the liver and adipose tissue. Increased PAI-1
evels are found in various disease states such as cancer,
besity, and metabolic syndrome.1,2 Thus, it has been
uggested that the increased incidence of thrombosis in
atients with these conditions may be associated with ele-
ated PAI-1 levels.1,2 A secondary role of the fibrinolytic
ystem is tissue remodeling, and u-PA mainly orchestrates
his function. Tissue remodeling in blood vessels is the
eorganization or renovation of existing tissues after an
njury, such as the changes that occur in the vein wall after
eep vein thrombosis (DVT).3 Tissue remodeling involves
he matrix metalloproteinases (MMPs), general proteolytic
nzymes, and monocyte chemotactic protein-1 (MCP-1)
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March 2012816 Diaz et althat are responsible for monocyte recruitment.3-5 u-PA
regulates both gene expression and protein synthesis of
MMP-2, MMP-9, and MCP-1.6,7
Hyperlipidemia has been established as a hypercoagu-
lable state as demonstrated in mice. Using a carotid artery
ferric chloride (FeCl3) model, apolipoprotein E gene-
deleted (ApoE-/-) mice have a faster occlusion time and
require shorter times of FeCl3 application to produce com-
plete occlusion, compared with controls.8,9 In addition,
some investigators have found a connection between hy-
perlipidemia and PAI-1,10-12 and others have established a
connection between PAI-1 andDVT.13-15 The objective of
this study was to characterize the ApoE-/- mice with
hyperlipidemia in the context of DVT. We hypothesized
that an increase in PAI-1 in ApoE-/-hyperlipidemic mice
would decrease fibrinolysis and promote venous thrombo-
sis in a mouse model of this disease.
METHODS
Animals
Male C57BL/6 wild-type (WT) mice (Charles River
Laboratories, Wilmington, Mass), ApoE-/-mice (Stock
#2052, Jackson Laboratories, Bar Harbor, Me) and PAI-
1-/-mice (Daniel Lawrence, PhD, University of Michigan,
Ann Arbor, Mich) were utilized in this study. The animals
were all 8 to 10 weeks in age and had an average weight of
24.3 grams (g) across the groups (WT: 24.0 g, ApoE-/-:
24.9 g, PAI-1-/-: 24.1 g). All work was approved by the
University of Michigan, University Committee on Use and
Care of Animals and was performed in compliance with the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health. The Uni-
versity of Michigan maintains accreditation by the Associ-
ation for the Assessment and Accreditation of Laboratory
Animal Care International (AAALAC).
Inferior vena cava (IVC) stasis model
ADVTmodel of IVC ligation, or stasis, was performed
as previously described.5 Briefly, mice were anesthetized via
inhalation of 2% isoflurane with 100% oxygen. A midline
laparotomy was performed with exteriorization of the in-
testines to expose the IVC. Dorsal branches were cauter-
ized and side branches were ligated with 7-0 Prolene (Ethi-
Table. Mice distribution
Blood Tissue
C57BL/6 (n122)
TC D2 D6 D14
PAI-1 u-PA (W/T) 5 10 10 10
Plasmin MCP-1 (W) 5 10 10 10
MMP2/9 (W) 5 12 10 10
Thrombus weight 15 32 30 30
Histology 5 5 5
ApoE-/-, Apolipoprotein E gene-deleted mice; C57BL/6, wild type mice;
MMP, matrix metalloproteinase; PAI-1, plasminogen activator inhibitor-1;
(DVT) mice; u-PA, urokinase-type plasminogen activator; W, vein wall; W/con, Inc, Somerville, NJ). The IVC was also ligated just telow the level of the renal veins. The abdominal cavity was
losed in a bilayer fashion using 5-0 Vicryl for abdominal
uscles and Vetbond tissue adhesive (3M Animal Care
roducts, St. Paul, Minn) for the skin. Mice were eutha-
ized at specific time points, post-thrombosis, for tissue
arvest and blood collection.5,16,17
xperimental design
We used ApoE-/-as the hyperlipidemic experimental
ice (fourfold increase in cholesterol and twofold increase
n triglycerides compared with WT, data not shown) and
T mice as controls for the majority of the assays in this
ork. In addition, a limited number of PAI-1-/-mice were
sed for thrombus weight determinations only. All animals
ere maintained on a normal rodent chow diet for the
uration of the study. The total numbers of mice utilized in
his study included ApoE-/-mice (n  126), WT (n 
22), and PAI-1-/-mice (n 35).Mice in each groupwere
tudied on either day 2 (acute time point), 6, or 14 (chronic
ime points) postsurgery.18,19 Mice that did not receive
urgery were used as true controls (TC), for baseline com-
arisons. Mice distribution used per each experiment in-
luded: n 5 for TC and at least n 10 for each DVT time
oint (Table). The number of animals per time point was
alculated based on power analysis of previous studies with
his model.20 At the time of euthanasia, bloodwas collected
y cardiocentesis, and the IVC, with its associated throm-
us, was harvested together for thrombus weight. The
hrombus was then removed from the IVC, each frozen
ndividually and then processed separately for themolecular
ssays. For histology, the harvested specimen included the
VC, its associated thrombus and the surrounding tissues
o ensure the complete visualization of the vein wall and
hrombus. Additional processing of the samples is de-
cribed further in the following paragraphs.
hrombus weight
On harvest day, the IVC and its associated thrombus
ere removed from anesthetized mice, weighed in grams
g), and measured for length in centimeters (cm). Throm-
us weight, which included the weight of the thrombus and
he weight of vein wall combined, was used as a reference of
ApoE-/- (n126) PAI-1-/- (n35)
TC D2 D6 D14 TC D2 D6 D14
5 10 10 10
5 12 10 12
5 11 10 11
15 33 30 33 5 10 10 10
5 5 5
6, D14, days after surgery; MCP-1, monocyte chemoattractant protein-1;
-/-, PAI-1 gene-deleted mice; TC, true control or no deep vein thrombosis
n wall and thrombus.D2, Dhrombosis.5
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PAI-1 activity assay. To measure active murine
PAI-1 concentrations in plasma samples, human uPA (rhe-
otromb) was coupled to carboxylated beads (Luminex,
Austin, Tex) and used to capture active PAI-1. A standard
curve was generated using known concentrations of murine
PAI-1 in PAI-1-depleted mouse plasma (Molecular Inno-
vations, Novi, Mich). The assay was performed by adding
10 L of either the standards or samples to a 96 well plate
filter plate (Millipore, Billerica, Mass). Each well then re-
ceived 10 L phosphate-buffered saline (PBS)-1% bovine
serum albumin and 5000 beads in 30 L of PBS-1% bovine
serum albumin. The wells were incubated overnight in the
dark at 4°C. The solution from each well was removed by
vacuum suctioning and each well was washed twice with
200 L PBS-0.05% Tween 20. The beads were mixed with
continuous shaking in the dark at room temperature for 1
hour with 50 L of 2 g/mL biotin-labeled rabbit anti-
mouse PAI-1 (Molecular Innovations). The wells were
vacuum washed and 25 L of 4 g/mL streptavidin-R-
phycoerythrin (Molecular Probes, Eugene, Ore) was added
to each well, and the mixture incubated in the dark with
continuous agitation at room temperature for 30 minutes.
Finally, the solution was removed from each well by vac-
uum suctioning, the beads were washed three times with
200 L of PBS-0.05% Tween 20, and 150 L of sheath
fluid was added for 5 to 10 minutes. The beads were then
read with a Luminex 100 (Luminex, Austin, Tex), median
setting, 100 L sample size, 100 events/bead.
Plasmin and u-PA activity assays. These assays quan-
tify the amount of active plasmin in mouse plasma and the
amount of active u-PA in mouse IVC wall samples and in
separate thrombus samples. Functionally active mouse plas-
min in citrated plasma samples bind to  2-antiplasmin
coated on the microtiter plate and only free active plasmin
enzyme reacts with the antiplasmin on the plate. Function-
ally active mouse u-PA in homogenized IVC or thrombus
samples bind to biotinylated human PAI-1 that is coated on
the microtiter plate. Then, monoclonal mouse antimurine
u-PA primary antibody binds to the captured u-PA, and
only free active u-PA reacts with the PAI-1 on the plate.
Samples were detected by a biotinylated antibody, followed
by the addition of tetramethylbenzadine (TMB) substrate
for color development, according to the manufacturer’s
protocol (Molecular Innovations). The plates were read on
an Elx808 plate reader (Bio-tek,Winooski, Vt) at a 450-nm
wavelength. To normalize the results, total protein was
measured by using a bicinchoninic acid protein assay kit
assessing colorimetric detection and quantification of total
protein, read at 590 nm (Pierce, Rockford, Ill).
Antigen determination
An enzyme-linked immunosorbent assay (ELISA) for
MCP-1 (R&D Systems, Minneapolis, Minn) was per-
formed on individual homogenized IVC wall specimens.
Samples were captured and then detected by a biotinylated
antibody, followed by tetramethylbenzadine (TMB) sub- ttrate according to themanufacturer’s protocol. The results
ere read on an Elx808 plate reader (Bio-tek, Winooski,
t) at a 450-nmwavelength. To normalize the results, total
rotein was measured by using a bicinchoninic acid protein
ssay kit assessing colorimetric detection and quantification
f total protein, read at 590 nm (Pierce, Rockford, Ill).
nalysis of the vein wall cellular components
morphometrics)
Histology samples were paraffin-embedded, cut in
-mm sections, processed as slides, stained with hematox-
lin and eosin (H&E), and examined under high-power
1000) oil immersion light microscopy.5 Five representa-
ive high-power fields (5 HPFs) were examined around the
ein wall for inflammatory cell counts and averaged. In-
ammatory cells were identified as neutrophils, mono-
ytes/macrophages, or lymphocytes on the basis of stan-
ard histologic criteria, including nuclear size, cytoplasmic
ontent, and total cell size, in a blinded manner by a
oard-certified veterinary pathologist.
ymography
Determination of MMP-2 and MMP-9. Gelatin
ubstrate zymography was performed using precast 10%
DS-polyacrylamide gels containing 1 mg/mL of gelatin
unless otherwise stated, all zymography supplies were
rom Novex, San Diego, Calif).21-23 IVC wall specimens
ere homogenized in SDS, centrifuged for 10 minutes at
000  g, and equal volumes of the supernatants were
iluted with tris-glycine-SDS sample buffer and electro-
horetically separated under nonreducing conditions. Sep-
rated proteins were renatured in 2.7% Triton X-100 for 2
ours to induce gelatin lysis by renatured MMPs. The gels
ere developed for 48 hours at 37°C in 50 mM Tris-HCL,
mM CaCl2, and 0.2% Brij 35 followed by staining with
oomassie blue and destaining in 10% acetic acid. Gelati-
ase or MMP activity was evident by clear bands against a
ark stained background where the substrate was degraded
y the enzyme. Samples containing human recombinant
MP-2 and MMP-9 (Oncogene, Boston, Mass) were in-
luded as standards. Concentrations of the densitometry
nalysis were performed using a FOTO/Analyst CCD
AMERA (Fotodyne, Hartland, Wisc) and GEL-Pro An-
lyzer software version 3.1 (Media Cybernetics, Silver
prings, Md). Ratios of optical densities/total protein were
alculated. To normalize the results, total protein was
easured by using a bicinchoninic acid protein assay kit
ssessing colorimetric detection and quantification of total
rotein, read at 590 nm (Pierce, Rockford, Ill).
tatistical analyses
All statistical analyses were performed using Graph Pad
rism version 5.01 for Windows (Graph Pad Software, San
iego, Calif). The statistical differences between groups
ere determined by a Student t test and a one-way analysis
f variance (ANOVA) with a Tukey’s multiple comparison
est performed between groups for additional comparisons.
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reported as mean  standard error of the mean (SEM).
RESULTS
Thrombus size was increased in mice with
hyperlipidemia. The thrombus weight was significantly
increased by 14%, in ApoE-/-mice at day 2 vsWT (0.036
0.001 g vs 0.032 0.001 g; P .05) and by 24% at day 14
(0.017  0.001g vs 0.013  0.001 g; P  .01). No
differences were observed at day 6. In PAI-1-/-mice, the
thrombus weight was significantly decreased at all time
points, compared with ApoE-/-mice. Thrombus weight
was 45% less at day 2 (0.020  0.005 vs 0.036  0.001 g;
P  .01); 33% less at day 6 (0.015  0.001g vs 0.030 
0.001g; P  .01) and 41% less at day 14 (0.010  0.001g
vs 0.017  0.001 g; P  .01) (Fig 1).
Fibrinolysis was impaired during acute DVT in
mice with hyperlipidemia. No significant differences
were observed in plasmin levels between ApoE-/-mice and
WT mice. However, a trend showed a decrease in plasmin
levels of 19% in ApoE-/-mice at day 2, compared with WT
(523  15 ng/mg vs 644  90ng/mg); 13% at day 6
(252 18 ng/mg vs 291 13 ng/mg) and 22% at day 14
(227  18 ng/mg vs 291  28 ng/mg) (Fig 2, A).
Levels of PAI-1 were significantly increased by 41% in
ApoE-/-mice compared with controls at day 2 (261  23
pg/mL vs 159 21pg/mL; P .05). No significant differ-
ences were observed at days 6 and 14, post DVT (Fig 2, B).
Impaired u-PA decreased thrombus resolution.
u-PA was detected in both vein wall and thrombus samples
in C57BL/6 mice. The highest u-PA levels in vein wall
were found at day 2, while the highest level of u-PA in the
thrombus was on day 6 in the controls. Undetectable levels
Fig 1. Thrombus size was increased in mice with hyperlipidemia.
The thrombus weight was significantly increased by 14%, in apoli-
poprotein E gene-deleted (ApoE-/-) mice at day 2 (P  .05), and
by 24% at day 14 (P .01), vs wild type (WT). No differences were
observed at day 6 between ApoE-/- andWTmice. In plasminogen
activator inhibitor-1 gene deleted (PAI-1-/-) mice, the thrombus
weight was significantly decreased at all time points compared with
ApoE-/-, 45% at day 2 (P .01); 33% at day 6 (P .01) and 41%
at day 14 (P  .01). TC, True controls.of u-PA were found in ApoE-/-mice at all time points in loth vein wall and thrombus (Fig 3). In ApoE-/-mice, vein
all MMP-2 was significantly decreased by 64% at day 6
ost thrombosis (105  13 ng/mg vs 304  17 ng/mg,
 .01) and 58% at day 14 (125 31 ng/mg vs 299 50
g/mg, P .05), compared withWT (Fig 4,A). Also, vein
all MMP-9 was significantly reduced by 71% in ApoE-/-
ice at day 2 (188  5 ng/mg vs 619  46 ng/mg, P 
01) and 48% at day 6 (128  32 ng/mg vs 248  16
g/mg, P  .01), compared with controls (Fig 4, B).
Vein wall MCP-1 was found to be significantly de-
reased by 38% in ApoE-/-mice, 2 days post DVT (1450
20 ng/mg vs 2293  172 ng/mg, P  .01), and 67% at
ay 6 (88  12 ng/mg vs 264  28 ng/mg, P  .01), vs
T (Fig 5, A). Finally, the monocyte cell counts were
ignificantly reduced by 41% at day 6 (4.5  0.8 mono-
ytes/5 HPF vs 7.6  0.9 monocytes/5 HPF, P  .01)
nd 39% at day 14 (6  0.7 monocytes/5 HPF vs 9.8  1
onocytes/5 HPF, P  .05) in ApoE-/-mice with hyper-
ig 2. The fibrinolytic system was impaired mainly at acute time
oint in mice with hyperlipidemia.A,A trend of decreased plasmin
evels in apolipoprotein E gene-deleted (ApoE-/-) mice compared
ith wild type (WT) was noted; 19% at day 2, 13% at day 6, and
2% at day 14. B, Levels of plasminogen activator inhibitor-1
PAI-1) were significantly increased by 41% in ApoE-/-mice, vs
T at day 2 (P .05). No significant differences were observed at
ays 6 and 14, post deep vein thrombosis (DVT). TC, True
ontrols.ipidemia, vs controls (Fig 5, B).
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The Justification for the Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin (JUPITER)
trial, published in 2009, documented a significant decrease
in the incidence of DVT in patients treated with statins.
Even though it brought to light the role of statins, hyper-
lipidemia, and inflammation in DVT,24 the mechanism
behind these findings was not addressed. Despite the fact
that it is not considered a risk factor of DVT, hyperlipid-
emia is associated with a hypercoagulable state as demon-
strated in mice studies.8,9 In addition, some investigators
have reported a link between hyperlipidemia and increased
levels of PAI-1 in humans and mice,10-12 and others have
found a link between PAI-1 and DVT,13-15 but up to this
point no connection between hyperlipidemia, PAI-1, and
DVT had been established. Thus, our aim was to determine
if hyperlipidemic animals are more prone to developing a
DVT through the effects of PAI-1. The balance between
plasminogen activators (t-PA and u-PA) and PAI-1 deter-
mines the overall activity of the fibrinolytic system. The
presence or activity of fibrinolytic proteins is able to be
Fig 3. The urokinase-type plasminogen activator (u-PA) system
was impaired in mice with hyperlipidemia. A, This graph showed
that it was possible to quantify levels of u-PA in both vein wall and
thrombus in C57BL/6 mice. B,Using the same assay for apolipo-
protein E gene-deleted (ApoE-/-) mice, undetectable levels of
u-PA were found at all time points in both the vein wall and
thrombus. TC, True controls.detected in circulation. In general, an increase of PAI-1 ioncentrations in plasma is associated with impaired fibri-
olysis, decreased plasmin activity, an increase in the accu-
ulation of fibrin, and a decreased activation of MMPs.25
ere, we present the first work documenting the kinetics of
VT in a model of hyperlipidemia in mice.
We used the IVC ligation model that has been well-
stablished and successful in producing consistent throm-
us formation within the IVC to study DVT. It has been
roadly used in multiple mouse strains and rats to study
oth acute venous thrombosis (2 days after ligation) and
hronic venous thrombosis (days 6 and 14 after IVC liga-
ion).3,18,19 Thrombus weight, a measurement of throm-
us size in our mouse model of DVT, was assessed at all
ime points. The ApoE-/-mice produced the largest
hrombus weights at days 2 and 14. This was an important
nitial finding in this work since, across the mouse strains,
e performed the identical surgery on mice that had similar
verage body weights, were comparable in age, housed
nder the same conditions, and fed the same normal rodent
iet.
Then, we investigated the fibrinolytic system. Our find-
ig 4. The decreased urokinase-type plasminogen activator (u-
A) system activity was reflected by matrix metalloproteinases
MMPs) in apolipoprotein E gene-deleted (ApoE-/-) mice. Zy-
ography results: A, Graph showing that the protein concentra-
ion of MMP-2 was significantly decreased at days 6 and 14 in the
ein wall. B, Graph showing the protein concentration of MMP-9
n the vein wall. It was significantly decreased at day 2 and day 6.
C, True controls.ngs during acute DVT (2 days after the IVC was ligated)
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March 2012820 Diaz et aldemonstrated a deficit in the functioning of the fibrinolytic
system when DVT occurs in hyperlipidemic mice. The
levels of PAI-1, the main inhibitor of the fibrinolytic sys-
tem, were significantly increased during acute thrombosis
in mice with hyperlipidemia. This correlated with a de-
creased level of plasmin, the enzyme responsible for fibrin
degradation that was found in ApoE-/-mice at the same
acute time point. When coagulation is triggered, multiple
events occur simultaneously, including fibrinolysis. If fibri-
nolysis does not respond according to the normal throm-
bogenesis in this mouse model of DVT, the result is an
increase in thrombus weight.
Thus, elevated levels of PAI-1 suggest impaired fibri-
nolysis in ApoE-/-mice that had a direct impact on throm-
bus weight, as observed with the increase in thrombus size
documented in mice with hyperlipidemia. To further dem-
onstrate that the increase in thrombus weight in ApoE-/-
mice was due to the increase in PAI-1 levels, similar surger-
ies were performed on PAI-1-/-mice. PAI-1-/-mice had
Fig 5. The decreased urokinase-type plasminogen activator
(u-PA) system activity was reflected by monocyte chemotactic
protein-1 (MCP-1) and monocyte recruitment in mice with hyper-
lipidemia.A, This graph shows the vein wall protein concentration
of MCP-1 to be significantly decreased by 38% at day 2 (P  .01)
and by 67% at day 6 (P .01) after deep vein thrombosis (DVT) in
apolipoprotein E gene-deleted (ApoE-/-) mice vs wild type (WT).
B, Monocyte cell counts, average counts of 5 high-power fields
(HPF) in at least five specimens per each time point, were signifi-
cantly reduced at day 6 (P .01) and day 14 (P .05) inmice with
hyperlipidemia vs controls. TC, True controls.the smallest thrombus sizes at all time points, compared Tith ApoE-/-mice. This significant reduction in the
hrombus weights of PAI-/-mice, suggest a relationship
etween PAI-1, DVT, and hyperlipidemia.
PAI-1 is the main inhibitor of u-PA, and recent infor-
ation regarding the u-PA system has shown that degra-
ation of fibrin is not the only function of the fibrinolytic
ystem. It has been demonstrated that in rat cortical astro-
ytes u-PA induces a rapid dose-dependent upregulation in
MP-2 and MMP-9 (by zymography) and also induces
levations in secreted MCP-1,6 providing evidence for the
ole of u-PA in orchestrating tissue remodeling. However,
he role of the u-PA system in “vein wall” remodeling is an
nderstudied area in the context of hyperlipidemia associ-
ted with DVT.
We investigated the u-PA system in hyperlipidemic
ice using the IVC ligation model. Undetectable levels of
-PA were found in both the vein wall and thrombus of
poE-/-mice. MMP-2, whose main effect is tissue remod-
ling at chronic time points, was significantly decreased at
ays 6 and 14. In addition, MMP-9 was significantly de-
reased at days 2 and 6. The participation of MMP-2 and
MP-9 in cell migration and thrombus resolution has
een previously established.3 The significant decrease that
e found in MMP-2 and -9, suggest impaired thrombus
esolution in the ApoE-/-mice, in comparison to the
ontrols.
The main function ofMCP-1 is to attract monocytes to
he vein wall to aid in the thrombus resolution process. We
ound that the protein levels of MCP-1 were significantly
ecreased in ApoE-/-mice, compared with WT mice. This
orrelated with a significant decrease in monocyte recruit-
ent at chronic time points. Monocytes are the main
ellular players for thrombus resolution, as was previously
emonstrated in rodents,4,26 and its significant reduction
ay contribute to the increased thrombus weights in
poE-/-mice that were observed at the most chronic time
oint.
These results suggest that during chronic DVT, the
poE -/-mice lack the ability to recruit monocytes to the
rea of thrombosis and to produce MMPs, well-known and
ey players in thrombus resolution, and correlates with the
ecreased thrombus resolution observed in ApoE-/-mice
uring the latter chronic time point. Since the only differ-
nce between ApoE-/- and WT mice in this work was
yperlipidemia, the significant decreases observed in the
arkers of tissue remodeling and thrombus resolution in
poE-/-mice reflects an impairment of thrombus reso-
ution.
A limitation of this study includes the fact that there
as no manipulation of PAI-1 levels in the hyperlipidemic
ice. To further demonstrate the PAI-1 mechanism, in the
ontext of hyperlipidemia, the use of ApoE/PAI-1double
/-mice would be appropriate or the use of a PAI-1 inhib-
tor in the ApoE -/-mice. Also, using other hyperlipidemic
ice such as low-density lipoprotein receptor-/- mice
ould be beneficial to further evaluate this mechanism.
hese are all part of our future direction.
R1
1
1
1
1
1
1
1
1
1
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Volume 55, Number 3 Diaz et al 821To our knowledge, this is the first time that a dysfunc-
tion in the fibrinolytic system has been characterized in
mice with hyperlipidemia, undergoing venous thrombosis.
During acute DVT, increased PAI-1 correlated with an
early increase in thrombus weight, due to impaired fibrino-
lysis suggesting that these hyperlipidemic mice are more
prone to developing DVT (Fig 6). In addition, undetect-
able levels of u-PA correlated with the decreases inMMP-2,
MMP-9, MCP-1, and monocyte recruitment observed
during chronic DVT, all key players in thrombus resolu-
tion, suggesting that this late mechanism was impaired (Fig
6). In summary, the elevation of PAI-1 activity found in
mice with hyperlipidemia, promoted thrombus amplifica-
tion and initiated a sequence of biologic events that re-
sulted in diminished thrombus resolution.
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Fig 6. Schematic representation of our findings. Fibrinolysis and
thrombus resolution were found to be impaired in mice with
hyperlipidemia undergoing deep vein thrombosis (DVT). In-
creased plasminogen activator inhibitor-1 (PAI-1) contributes to
an early increase in thrombus size, due to impaired fibrinolysis.
Additionally, undetectable levels of urokinase-type plasminogen
activator (u-PA) led to decreased vein wall matrix metalloprotei-
nase (MMP)-2 and MMP-9, and lower levels of monocyte chemo-
tactic protein-1 (MCP-1) affecting monocyte recruitment, thus
impairing thrombus resolution. ApoE-/-, Apolipoprotein E
gene-deleted.Overall responsibility: JD, TWEFERENCES
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